Wall Street brokerages expect that Teva Pharmaceutical Industries Ltd (NYSE:TEVA) will post earnings per share (EPS) of $0.61 for the current quarter, according to Zacks. Seven analysts have provided estimates for Teva Pharmaceutical Industries’ earnings. The lowest EPS estimate is $0.56 and the highest is $0.67. Teva Pharmaceutical Industries posted earnings of $0.53 per share in the same quarter last year, which would suggest a positive year over year growth rate of 15.1%. The firm is scheduled to issue its next quarterly earnings report on Wednesday, February 12th.
On average, analysts expect that Teva Pharmaceutical Industries will report full-year earnings of $2.38 per share for the current financial year, with EPS estimates ranging from $2.25 to $2.48. For the next year, analysts expect that the company will report earnings of $2.52 per share, with EPS estimates ranging from $2.36 to $2.76. Zacks’ earnings per share averages are an average based on a survey of research firms that follow Teva Pharmaceutical Industries.
Teva Pharmaceutical Industries (NYSE:TEVA) last issued its quarterly earnings data on Wednesday, August 7th. The company reported $0.57 EPS for the quarter, topping analysts’ consensus estimates of $0.55 by $0.02. Teva Pharmaceutical Industries had a negative net margin of 21.94% and a positive return on equity of 16.04%. The firm had revenue of $4.34 billion for the quarter, compared to analyst estimates of $4.25 billion. During the same quarter in the previous year, the business posted $0.78 EPS. The firm’s revenue was down 7.7% compared to the same quarter last year.
TEVA stock traded up $0.83 during trading on Tuesday, reaching $9.30. The stock had a trading volume of 34,192,717 shares, compared to its average volume of 16,922,125. Teva Pharmaceutical Industries has a 1-year low of $6.07 and a 1-year high of $23.97. The company has a current ratio of 0.96, a quick ratio of 0.62 and a debt-to-equity ratio of 1.73. The company has a market capitalization of $9.32 billion, a P/E ratio of 3.32, a PEG ratio of 0.89 and a beta of 1.73. The firm has a fifty day moving average price of $7.51 and a 200 day moving average price of $8.90.
Several institutional investors have recently modified their holdings of the company. DNB Asset Management AS raised its stake in Teva Pharmaceutical Industries by 10.9% during the second quarter. DNB Asset Management AS now owns 85,262 shares of the company’s stock worth $787,000 after acquiring an additional 8,379 shares during the period. Sanders Morris Harris LLC acquired a new stake in Teva Pharmaceutical Industries during the second quarter worth about $76,000. Exane Derivatives raised its stake in Teva Pharmaceutical Industries by 470.2% during the second quarter. Exane Derivatives now owns 53,093 shares of the company’s stock worth $490,000 after acquiring an additional 43,782 shares during the period. Xact Kapitalforvaltning AB raised its stake in Teva Pharmaceutical Industries by 37.2% during the second quarter. Xact Kapitalforvaltning AB now owns 39,100 shares of the company’s stock worth $361,000 after acquiring an additional 10,600 shares during the period. Finally, Bridge Creek Capital Management LLC raised its stake in Teva Pharmaceutical Industries by 9.3% during the second quarter. Bridge Creek Capital Management LLC now owns 30,425 shares of the company’s stock worth $281,000 after acquiring an additional 2,600 shares during the period. Institutional investors and hedge funds own 58.21% of the company’s stock.
About Teva Pharmaceutical Industries
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide. It operates through two segments, Generic Medicines and Specialty Medicines. The Generic Medicines segment offers sterile products, hormones, narcotics, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams.
Recommended Story: What does a hold rating mean?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.